3Powers AC.Diabetes Mellitus.In:Kasper,Braunwald,Fauci,wds.Harrison's Principles of Internal Medicine editors.16th ed,2005.2152-2180.
4Buse JB.Management of Type2 Diabetes Mellitus.In:DeGroot and Jameson.Endocrinology.5th ed,2006.1231-1248.
5Page S.Insulin initiation in Type 2 diabetes.Diabet Med,2005,22 (suppl 4):2-5.
6ChriTian W,Pratley RE,Tataranni PA.Role of insulin resitance and inslin secretory dysfunction in the pathogeneysis of type2 diabetes mellitus.Curr Opin Endocrinol Diab,2002,9:130-138.
2Purrello F, Rabuazza AM. Metabolic factors that affect beta-cell function and survival [J]. Diabet Nutr Metab, 2000,13(2) :84-91.
3John P, Dphil F. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes[J]. Diabetes Care, 2002,25 (3) : 593-598.
4Saha ME, Huuppone T, Mikael K, et al. Continuous subcutaneous insulin infusion in the treatment of children and adolescents with type 1 diabetes mellitus[J]. J Pediatr Endocrinol Metab, 2002,15 (7) : 1005-1010.
5Kahn SE. The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus[J]. Am J Med, 2000,108(Suppl 6a) :2-8.
6Svitiz WI. Lipotoxicity and glucotoeieity in type 2 diabetes. Effects on development and progression [J]. Postgrad Med,2001,109(1) :55-64.